Adverum Biotechnologies, Inc. (NASDAQ: ADVM)
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Assembly Biosciences (NASDAQ:ASMB) launches a public offering of common stock. Price, volume and terms have yet to be announced.
Shares down 4% after hours.
Gilead Sciences (NASDAQ:GILD) unit Kite has submitted a marketing application to the FDA seeking approval for CAR T therapy KTE-X19 for the treatment of adults with relapsed/refractory mantle cell lymphoma, a type of slow-growing NHL.
The company plans to file an application in Europe next quarter.
Endonovo Therapeutics (OTCQB:ENDV -33.3%) announced it has determined to effect a 1-for-1,000 reverse stock split of the Company’s issued common shares.
The reverse stock split will take effect, after completing FINRA review under the existing ticker symbol “ENDVD”.
This will reduce the number of outstanding shares of the Company’s common stock from ~1,005,306,406 million shares to ~100,530 shares.
Novartis (NVS -0.1%) inks an agreement with Finnish biotech Forendo Pharma aimed at discovering new drugs for chronic liver diseases.
Under the terms of the deal, Forendo will receive an upfront payment, research funding, milestones and tiered royalties on net sales in addition to an equity stake from the Swiss drugmaker.
Novartis will take over all development, manufacturing and commercialization activities after the end of the research collaboration.
The Helsinki-based drug developer’s core expertise is in an enzyme family called HSD17B (17-beta-hydroxysteroid dehydrogenase) that plays a key role in regulating hormone action. Its lead program is FOR-6219, an HSD17B inhibitor, in Phase 1b for endometriosis.
Thinly traded nano cap Genetic Technologies Limited (GENE +21.6%) is up on almost a 5x surge in volume, albeit on turnover of only 149K shares, in response to its announcement that sales of its third-generation breast cancer test should commence next quarter.
The company aims to set up 12 clinical sites to demonstrate utility, user experience, reimbursement and distribution.
The test, called Genetype for Breast Cancer, predicts the risk of disease by combining DNA and mammography data.
